OncoSec Medical Inc.

404 articles with OncoSec Medical Inc.

• OncoSec Announces Pricing of $3.5 Million Public Offering

  11/30/2022

  OncoSec Medical Incorporated announced the pricing of its "reasonable best efforts" public offering of 1,166,667 shares of common stock and Common Warrants to purchase 1,166,667 shares of common stock at a combined price of $3.00 per share, for aggregate gross proceeds of $3.5 million, before deducting placement agent fees and other offering expenses.

• OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma

  11/15/2022

  OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced early clinical data from an investigator-sponsored trial (IST) conducted by Dr. Ahmad Tarhini at the H. Lee Moffit Cancer Center & Research Institute.

• OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

  11/11/2022

  OncoSec Medical Incorporated today announced data from the Phase 2 KEYNOTE-695 clinical trial.

• OncoSec Announces Reverse Stock Split - November 08, 2022

  11/8/2022

  OncoSec Medical Incorporated announced it intends to effect a 1-for-22 reverse split of its issued and outstanding common stock.

• 

  OncoSec Slashes Headcount by Almost Half, Goes All-In on Lead Candidate

  10/5/2022

  OncoSec Medical Inc. announced Tuesday that it was laying off around 45% of its workforce to focus its resources on the development of its lead asset TAVO-EP.

• OncoSec Announces Pipeline Prioritization and Workforce Reduction

  10/4/2022

  OncoSec Medical Incorporated announced a corporate restructuring intended to prioritize development of its lead clinical candidate TAVO™ a plasmid encoding interleukin 12 delivered by intratumoral electroporation, and extend the Company's cash runway.

• Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research

  6/24/2022

  Results demonstrate novel synergistic effects of IL-12 and T cell receptor signaling in anti-tumor immunity.

• OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research

  5/23/2022

  OncoSec Medical Incorporated announced that it is the recipient of the 2022 Vanguard Award presented by the Triple Negative Breast Cancer Foundation.

• OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

  4/29/2022

  OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), today announced the appointment of Robert H. Arch, Ph.D., as President and Chief Executive Officer.

• OncoSec Announces Appointment of George Chi as Chief Financial Officer

  2/22/2022

  OncoSec Medical Incorporated, a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, announced the appointment of George Chi as Chief Financial Officer.

• OncoSec Announces Changes to its Board of Directors

  12/17/2021

  OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), today announced that Margaret Dalesandro, Ph.D., Chair of the Board of Directors and member of the Leadership Committee, has resigned from the Board of Directors and the Leadership Committee, effective immediately, and Dr. Linda Shi, M.D., Ph.D., has been added to the OncoSec Board of Directors and appointed Chair.  

• OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

  11/2/2021

  OncoSec Medical Incorporated will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET featuring key opinion leaders (KOLs) Matteo Carlino , MD

• OncoSec Provides Business Update

  10/20/2021

  OncoSec Medical Incorporated today announced that Chris Twitty , Ph.D., Chief Scientific Officer,

• OncoSec Provides Leadership Update

  8/16/2021

  OncoSec Medical Incorporated announced the establishment of a Leadership Committee consisting of three board members, Margaret Dalesandro, Ph.D., Herbert Kim Lyerly, M.D. and Yuhang Zhao, Ph.D., MBA, to lead all development efforts, with a focus on the Company's lead asset, TAVO™.

• OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

  7/26/2021

  OncoSec Medical Incorporated today announced that Interim CEO and Chief Operating Officer, Brian Leuthner , and Senior Vice President, Chief Clinical Development Officer, Sandra Aung , Ph.D., will participate in a fireside chat at the BTIG Virtual Biotechnology Conference

• OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering

  6/14/2021

  Mr. Silverman joins OncoSec with over two decades of electroporation device quality and manufacturing experience.

• OncoSec to Present at the Raymond James Human Health Innovation Conference

  5/27/2021

  - OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at the Raymond James Human Health Innovation Conference being held virtually Monday, June 21 st – Wednesday, June 23 rd , 2021.

• OncoSec Appoints Robert M. Schinagl, Ph.D. as Vice President of Program and Alliance Management

  5/17/2021

  Biotech industry veteran brings over 20 years of project and alliance management experience largely focused on oncology and clinical development

• OncoSec Receives CE Mark Certification for its Commercial Electroporation Device GenPulse™ for the Treatment of Solid Tumors

  4/14/2021

  OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced that it has received authorization to CE mark its proprietary next generation go-to-market gene delivery device, GenPulse™, a part of the OncoSec Medical System (OMS) electroporation device platform for use in solid tumors.

• OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

  3/25/2021

  Results From ILLUMINATE-301 To Be Discussed Webinar To Be Held on Wednesday, March 31, 2021 at 12:00 p.m. ET.